LEADER 04436nam 22006254a 450 001 9910818150503321 005 20230721031931.0 010 $a1-281-97519-2 010 $a9786611975197 010 $a1-934559-87-3 035 $a(CKB)1000000000481748 035 $a(EBL)322479 035 $a(OCoLC)335627674 035 $a(SSID)ssj0000218142 035 $a(PQKBManifestationID)11181563 035 $a(PQKBTitleCode)TC0000218142 035 $a(PQKBWorkID)10213318 035 $a(PQKB)10622574 035 $a(MiAaPQ)EBC322479 035 $a(Au-PeEL)EBL322479 035 $a(CaPaEBR)ebr10210545 035 $a(CaONFJC)MIL197519 035 $a(OCoLC)191726483 035 $a(EXLCZ)991000000000481748 100 $a20070806d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aParkinson's disease$b[electronic resource] $ediagnosis and clinical management /$fedited by Stewart A. Factor, William J. Weiner 205 $a2nd ed., rev. and updated. 210 $aNew York $cDemos$dc2008 215 $a1 online resource (858 p.) 300 $aDescription based upon print version of record. 311 $a1-933864-99-0 311 $a1-933864-00-1 320 $aIncludes bibliographical references and index. 327 $aCover; Title Page; Table of Contents; Foreword; Preface; Acknowledgments; Contributors; 1. James Parkinson: The Man and the Essay; 2. Paralysis Agitans in the Nineteenth Century; 3. Charcot and Parkinson's Disease; 4. Timeline of Parkinson's Disease History Since 1900; 5. Epidemiology; 6. Cardinal Features of Early Parkinson's Disease; 7. Gait Disturbances; 8. Sensory Symptoms; 9. Voice, Speech, and Swallowing Disorders; 10. Gastrointestinal Features; 11. Autonomic Dysfunction; 12. Sleep Disorders; 13. Natural History; 14. Clinical Rating Scales; 15. Dementia; 16. Depression 327 $a17. Anxiety and Panic18. Apathy and Amotivation; 19. Impulse-control Disorders; 20. Neuropathology; 21. Neurochemistry; 22. Basal Ganglia: Anatomy and Physiology; 23. Dopamine Receptor Diversity; 24. Status of Biological Markers; 25. Positron Emission Tomography; 26. Single Photon Emission Computed Tomography; 27. Magnetic Resonance Imaging; 28. Controversies in Neuroimaging; 29. Animal Models; 30. Pathogenesis: Oxidative Stress, Mitochondrial Dysfunction, and Excitotoxicity; 31. The Concept and Mechanisms of Programmed Cell Death; 32. Protein Aggregation 327 $a33. Etiology: The Role of Environment and Genetics34. The Impact of MPTP on Parkinson's Disease Research: Past, Present, and Future; 35. Rotenone and Other Toxins; 36. Inflammation; 37. Genetics; 38. Levodopa: A Pharmacologic Miracle Four Decades Later; 39. Amantadine and Anticholinergics; 40. Monoamine Oxidase Inhibitors; 41. Dopamine Agonists; 42. Catechol-O-Methyltransferase Inhibitors; 43. Excitatory Amino Acid Antagonists; 44. Adenosine A2A Receptor Antagonists; 45. Complementary and Alternative Medicine; 46. Motor Fluctuations and Dyskinesia; 47. Fluctuations of Nonmotor Symptoms 327 $a48. Psychosis and Other Behaviors49. Treatment of Dementia; 50. Status of Neuroprotective Therapies; 51. Symptomatic Treatment Approaches for Early Parkinson's Disease; 52. Progress in Gene Therapy; 53. Genetic Testing; 54. Deep Brain Stimulation; 55. Neural Transplantation: Yesterday, Today, and Tomorrow; 56. Stereotactic Pallidotomy and Thalamotomy; 57. Parkinson's-plus Disorders; 58. Symptomatic Parkinsonism; 59. Outcome Measures; 60. Family Caregiving; 61. Economics; 62. Driving; 63. The Patient's Perspective; Index 330 $aParkinson's disease (PD) is the second most common neurodegenerative disease in the world. Still the only major text on the subject, the completely revised and updated second edition of Parkinson's Disease: Diagnosis and Clinical Management comes at a time when specialists have made important advances in our understanding of the etiology, pathogenesis, investigation, and management of Parkinson's disease. 606 $aParkinson's disease 615 0$aParkinson's disease. 676 $a616.8/33 701 $aFactor$b Stewart A.$f1956-$0990788 701 $aWeiner$b William J$0316108 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910818150503321 996 $aParkinson's disease$93937526 997 $aUNINA